Clinical Impact of Eribulin in the Treatment of Breast Cancer

References

• Jemal A , SiegelR, XuJ, WardE. Cancer statistics, 2010. CA Cancer J. Clin.60(5), 277–300 (2010).
   PubMed Web of Science ®Google Scholar
• Johnson RH , ChienFL, BleyerA. Incidence of breast cancer with distant involvement among women in the United States, 1976 to 2009. JAMA309(8), 800–805 (2013).
   PubMed Web of Science ®Google Scholar
• National Cancer Institute . SEER Stat fact sheets: breast. http://seer.cancer.gov/statfacts/html/breast.html.
   Google Scholar
• American Cancer Society . Breast cancer facts & figures 2011–2012. www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-030975.pdf.
   Google Scholar
• Brewster AM , HortobagyiGN, BroglioKRet al. Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J. Natl Cancer Inst.100(16), 1179–1183 (2008).
   PubMedGoogle Scholar
• National Comprehensive Cancer Network . NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)®: breast cancer. Version 3 2013. National Comprehensive Cancer Network, PA, USA (2013).
   Google Scholar
• Halaven® (eribulin mesylate) injection (prescribing information). Eisai Inc., NJ, USA (2013).
   Google Scholar
• US FDA . FDA approves new treatment option for late-stage breast cancer. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm233863.htm.
   Google Scholar
• Cortes J , O’ShaughnessyJ, LoeschDet al. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a Phase 3 open-label randomised study. Lancet377(9769), 914–923 (2011).
   PubMed Web of Science ®Google Scholar
• Preston JN , TrivediMV. Eribulin: a novel cytotoxic chemotherapy agent. Ann. Pharmacother.46(6), 802–811 (2012).
   PubMed Web of Science ®Google Scholar
• Jordan MA , KamathK, MannaTet al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol. Cancer Ther.4(7), 1086–1095 (2005).
   PubMed Web of Science ®Google Scholar
• Okouneva T , AzarenkoO, WilsonL, LittlefieldBA, JordanMA. Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol. Cancer Ther.7(7), 2003–2011 (2008).
   PubMed Web of Science ®Google Scholar
• Smith JA , WilsonL, AzarenkoOet al. Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry49(6), 1331–1337 (2010).
   PubMed Web of Science ®Google Scholar
• Swami U , ChaudharyI, GhalibMH, GoelS. Eribulin – a review of preclinical and clinical studies. Crit. Rev. Oncol. Hematol.81(2), 163–184 (2012).
   PubMed Web of Science ®Google Scholar
• Jordan MA , KamathK. How do microtubule-targeted drugs work? An overview. Curr. Cancer Drug Targets7(8), 730–742 (2007).
   PubMed Web of Science ®Google Scholar
• Gourmelon C , FrenelJS, CamponeM. Eribulin mesylate for the treatment of late-stage breast cancer. Expert Opin. Pharmacother.12(18), 2883–2890 (2011).
   PubMed Web of Science ®Google Scholar
• Zhang ZY , KingBM, PelletierRD, WongYN. Delineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4. Cancer Chemother. Pharmacol.62(4), 707–716 (2008).
   PubMed Web of Science ®Google Scholar
• Devriese LA , Mergui-RoelvinkM, WandersJet al. Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole. Invest. New Drugs31(2), 381–389 (2013).
   PubMed Web of Science ®Google Scholar
• Devriese LA , WitteveenPE, WandersJet al. Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin. Br. J. Clin. Pharmacol.75(2), 507–515 (2013).
   PubMed Web of Science ®Google Scholar
• Zheng W , SeletskyBM, PalmeMHet al. Structure–activity relationships of synthetic halichondrin B analog E7389: in vitro susceptibility to PgP-mediated drug efflux. Presented at: Proceedings of the 94th Annual Meeting of the American Association for Cancer Research.44(2), Abstract 5751 (2003).
   Google Scholar
• Goel S , MitaAC, MitaMet al. A Phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies. Clin. Cancer Res.15(12), 4207–4212 (2009).
   PubMed Web of Science ®Google Scholar
• Synold TW , Tsao-WeiDD, QuinnDIet al. Phase I and pharmacokinetic (PK) study of eribulin (E7389) in patients (pts) with renal dysfunction (RD) and advanced urothelial cancer (UC): a California Cancer Consortium Trial [abstract]. J. Clin. Oncol.28(Suppl. 15), Abstract 2527 (2010).
   Web of Science ®Google Scholar
• Vahdat LT , PruittB, FabianCJet al. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J. Clin. Oncol.27(18), 2954–2961 (2009).
   PubMed Web of Science ®Google Scholar
• Cortes J , VahdatL, BlumJLet al. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J. Clin. Oncol.28(25), 3922–3928 (2010).
   PubMed Web of Science ®Google Scholar
• Aogi K , IwataH, MasudaNet al. A Phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer. Ann. Oncol.23(6), 1441–1448 (2012).
   PubMed Web of Science ®Google Scholar
• McIntyre K , O’ShaughnessyJ, SchwartzbergLet al. Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer. Breast Cancer Res. Treat.146(2), 321–328 (2014).
   PubMed Web of Science ®Google Scholar
• Wilks S , PuhallaS, O’ShaughnessyJet al. Phase 2, multicenter, single-arm study of eribulin mesylate plus trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer. Clin. Breast Cancer doi:10.1016/j.clbc.2014.04.004 (2014) ( Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Smith JW , RegeJ, ManiarH, SongJ, CoxD, O’ShaughnessyJ. Eribulin mesylate (Erib) plus capecitabine (X) for adjuvant treatment in post-menopausal estrogen receptor-positive (ER+) early-stage breast cancer: Phase II, multicenter, single-arm study [abstract]. J. Clin. Oncol.31(Suppl. 15), Abstract 563 (2013).
   Web of Science ®Google Scholar
• Traina TA , HudisC, FornierMet al. Adjuvant treatment of early-stage breast cancer with eribulin mesylate following dose-dense doxorubicin and cyclophosphamide: preliminary results from a Phase 2, single-arm feasibility study [abstract]. Cancer Res.72(Suppl. 24), 199S (Abstract P1–13–11) (2012).
   Google Scholar
• Cortes J , MonteroAJ, GluckS. Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer. Cancer Treat. Rev.38(2), 143–151 (2012).
   PubMed Web of Science ®Google Scholar
• Vahdat LT , GarciaA, VogelCLet al. Comparison of the incidence of peripheral neuropathy (PN) with eribulin versus ixabepilone (IXA) in metastatic breast cancer (MBC) patients: a randomized Phase II study [abstract]. J. Clin. Oncol.30(Suppl. 27), Abstract 121 (2012).
   Web of Science ®Google Scholar
• Faria C , LiX, PowersA, VahdatLT. Effects of dose modification of eribulin mesylate in patients with locally recurrent or metastatic breast cancer [abstract]. J. Clin. Oncol.31(Suppl. 26), Abstract 157 (2013).
   Web of Science ®Google Scholar
• Kaufman PA , AwadaA, TwelvesCet al. A Phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes [abstract]. Cancer Res.72(Suppl. 24), 109s (Abstract S6–6) (2012).
   Google Scholar
• Kaufman PA , CortesJ, AwadaAet al. A Phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: subgroup analyses [abstract]. J. Clin. Oncol.31(Suppl. 15), Abstract 1049 (2013).
   Google Scholar
• Muss H , CortesJ, VahdatLTet al. Eribulin monotherapy in patients aged 70 years and older with metastatic breast cancer. Oncologist19(4), 318–327 (2014).
   PubMed Web of Science ®Google Scholar
• Dranitsaris G , TripathyD, BeegleNL, KalbererTL, CoxJD, FariaC. Real-world analysis of eribulin in metastatic breast cancer (MBC): an assessment of time to treatment failure (TTF) in a community oncology setting. [abstract]. J. Clin. Oncol.31(Suppl. 26), Abstract 174 (2013).
   Web of Science ®Google Scholar
• Dranitsaris G , BeegleN, KalbererT, BlauS, CoxD, FariaC. A comparison of toxicity and health care resource use between eribulin, capecitabine, gemcitabine, and vinorelbine in patients with metastatic breast cancer treated in a community oncology setting. J. Oncol. Pharm. Pract. doi:1078155214525369 (2014) ( Epub ahead of print).
   Web of Science ®Google Scholar
• Gamucci T , MichelottiA, PizzutiLet al. Eribulin mesylate in pretreated breast cancer patients: a multicenter retrospective observational study. J. Cancer5(5), 320–327 (2014).
   PubMed Web of Science ®Google Scholar
• Poletti P , GhilardiV, LivraghiL, MilesiL, RotaCE, TondiniC. Eribulin mesylate in heavily pretreated metastatic breast cancer patients: current practice in an Italian community hospital. Future Oncol.10(2), 233–239 (2014).
   PubMed Web of Science ®Google Scholar
• Ramaswami R , O’CathailSM, BrindleyJH, SilcocksP, MahmoudS, PalmieriC. Activity of eribulin mesylate in heavily pretreated breast cancer granted access via the Cancer Drugs Fund. Future Oncol.10(3), 363–376 (2014).
   PubMed Web of Science ®Google Scholar
• Faria C , BelkK, CraverC, McBrideA. Impact of treatment modification on treatment duration in metastatic breast cancer patients treated with eribulin mesylate [abstract]. Value-Based Cancer Care4(3), 26 (2013).
   Google Scholar